XML 37 R20.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Balance Sheet Components
 12 Months Ended
Mar. 31, 2024
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Components Balance Sheet Components
Prepaid Expense and Other Current Assets

Prepaid expense and other current assets consisted of the following:
March 31, 2024March 31, 2023
(in thousands)
Prepaid expenses$9,296 $13,244 
Other receivables5,751 3,003 
Other current assets1,794 2,977 
Prepaid expenses and other current assets$16,841 $19,224 
Property and Equipment, Net
Property and equipment, net consisted of the following:
March 31, 2024March 31, 2023
(in thousands)
Computer equipment and software$7,485 $10,376 
Laboratory equipment and software51,635 52,785 
Furniture and office equipment8,929 8,946 
Leasehold improvements41,180 40,964 
Capitalized asset retirement obligations853 853 
Property and equipment, gross110,082 113,924 
Less: accumulated depreciation and amortization(81,731)(75,316)
Property and equipment, net$28,351 $38,608 
Depreciation and amortization expense was $11.0 million, $14.8 million and $16.1 million for the fiscal years ended March 31, 2024, 2023 and 2022, respectively. For the fiscal year ended March 31, 2024, the Company wrote off fully depreciated property and equipment, which is no longer in use, with a cost basis of $4.6 million. For the fiscal year ended March 31, 2023, write offs of fully depreciated property and equipment were immaterial. There were no impairments to property and equipment for the fiscal years ended March 31, 2024 and 2022. There was an immaterial impairment to property and equipment for the fiscal year ended March 31, 2023.
Operating Lease Right-Of-Use Assets, Net
Operating lease right-of-use assets, net consisted of the following:
March 31, 2024March 31, 2023
(in thousands)
Operating lease right-of-use assets85,166 85,408 
Less: accumulated amortization(36,272)(29,330)
Operating lease right-of-use assets, net48,894 56,078 
Internal-Use Software, Net
Internal-use software, net consisted of the following:
 March 31, 2024March 31, 2023
 
(in thousands)
Capitalized internal-use software$35,918 $25,180 
Less: accumulated amortization(15,402)(9,519)
Internal-use software, net$20,516 $15,661 
During the fiscal years ended March 31, 2024, 2023, and 2022, the Company capitalized $12.1 million, $10.8 million, and $5.7 million respectively, in internal-use software, including $3.6 million, $3.2 million, and $1.2 million, respectively, of stock-based compensation expense. For the fiscal years ended March 31, 2024, 2023 and 2022, amortization and impairment of internal-use software was $6.3 million, $4.8 million and $2.9 million, respectively.
In addition, during the fiscal year ended March 31, 2024, the Company wrote-off $1.1 million of internal-use software related to the disposition of Lemonaid Health Limited; refer to Note 19, “Disposition of Subsidiary” for additional information. During the fiscal years ended March 31, 2024, 2023, and 2022, the Company recorded immaterial impairment charges related to internal-use software that will not be utilized in the future.
Intangible Assets, Net
Intangible assets, net consisted of the following:
March 31, 2024
Weighted Average Remaining
Useful Life
(Years)		Gross Carrying Amount
Accumulated Amortization
Net Carrying Amount
(in thousands, except years)
Customer relationships0.0$14,900 $(14,900)$— 
Partnerships7.69,000 (2,175)6,825 
Trademark2.611,000 (5,317)5,683 
Developed technology4.624,100 (8,320)15,780 
Non-compete agreements2.62,800 (1,353)1,447 
Patents4.55,500 (1,980)3,520 
Total intangible assets$67,300 $(34,045)$33,255 
March 31, 2023
Weighted Average Remaining Useful
Life
(Years)		Gross Carrying Amount
Accumulated Amortization
Cumulative Impairment ChargeCumulative Currency TranslationNet Carrying Amount
(in thousands, except years)
Customer relationships0.6$14,900 $(10,554)$— $— $4,346 
Partnerships8.623,200 (4,385)(9,968)(1,122)7,725 
Trademark3.611,000 (3,117)— — 7,883 
Developed technology5.624,100 (4,877)— — 19,223 
Non-compete agreements3.62,800 (793)— — 2,007 
Patents5.55,500 (1,164)— — 4,336 
Total intangible assets$81,500 $(24,890)$(9,968)$(1,122)$45,520 
Amortization expense for intangible assets was $12.3 million, $17.3 million and $7.6 million for the fiscal years ended March 31, 2024, 2023 and 2022, respectively.
During the third quarter of the fiscal year ended March 31, 2023, due to decreased revenue associated with a delayed product launch and margin forecasts for the U.K. partnership business, the Company performed an interim quantitative impairment test for the U.K. partnership asset group as of December 31, 2022. The fair value of the asset group was calculated using a discounted cash flow and was determined to be lower than its carrying value. As a result, the Company recorded a $10.0 million impairment charge to write down the value of the partnership intangible asset to its estimated fair value. The charge was recorded within sales and marketing expenses in its Consumer and Research Services segment in the consolidated statements of operations and comprehensive loss. There was no impairment to intangible assets during the years ended March 31, 2024 and March 31, 2022.
Estimated future amortization expense of the identified intangible assets as of March 31, 2024 was as follows:
Estimated Amortization
(in thousands)
Fiscal years ending March 31,
2025$7,919 
20267,919 
20276,769 
20285,006 
20293,176 
Thereafter2,466 
Total estimated future amortization expense$33,255 
Goodwill

The following table presents the changes in the carrying amount of goodwill for the Consumer and Research Services reporting unit:
Carrying Amount
(in thousands)
As of March 31, 2023$351,744 
Less: Impairment(351,744)
As of March 31, 2024$— 
In connection with its annual goodwill impairment assessment as of January 1, 2024, the Company identified a sustained decline in market capitalization, based on the Company’s publicly quoted share price, lower than expected financial performance and macroeconomic conditions that existed as of December 31, 2023. The Company performed an impairment assessment of goodwill acquired as part of the Lemonaid Health acquisition. The valuation of goodwill is a Level 3 non-recurring fair value measurement determined by utilizing the income approach (discounted cash flow method) corroborated by the market approach (guideline public company method). The Company recognized a non-cash, pre-tax goodwill impairment charge of $198.8 million as of December 31, 2023.
Subsequent to the annual impairment testing, in connection with the preparation of the financial statements for the year ended March 31, 2024, the Company identified a further sustained decline in market capitalization, based on our publicly quoted share price, requiring an interim impairment test of goodwill as of March 31, 2024. The Company performed an interim step one quantitative test for its Consumer and Research Services segment and determined that the estimated fair value of the reporting unit was less than its carrying value. The Company utilized the market approach to perform its goodwill impairment test as of March 31, 2024. Based on the result of interim goodwill impairment test as of March 31, 2024, the Company recorded an additional non-cash, pre-tax goodwill impairment charge of $152.9 million to write off the remaining balance of the Consumer and Research Services reporting unit’s goodwill, resulting in a total goodwill impairment charge of $351.7 million for the year ended March 31, 2024. As of March 31, 2024, the Company’s goodwill was fully impaired and no balance remained.
For the year ended March 31, 2024, the goodwill impairment charges were included in the consolidated statements of operations and comprehensive loss in the Consumer and Research Services segment. There were no impairment charges to goodwill for the fiscal years ended March 31, 2023 and 2022.
Accrued Expense and Other Current Liabilities
Accrued expense and other current liabilities consisted of the following:
March 31, 2024March 31, 2023
(in thousands)
Accrued payables$12,957 $17,030 
Accrued compensation and benefits4,266 5,898 
Accrued vacation7,221 8,839 
Accrued bonus7,420 21,600 
Accrued clinical expenses9,291 11,707 
Accrued taxes and other1,108 1,356 
Total accrued expenses and other current liabilities$42,263 $66,430